NEW YORK, NY / ACCESS Newswire / October 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arcturus Therapeutics Holdings Inc. ("Arcturus Therapeutics Holdings Inc.") (NASDAQ:ARCT) concerning possible violations of federal securities laws.

Arcturus issued a press release on October 22, 2025, "announcing interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for people with cystic fibrosis." The press release disclosed that patients in the trial had not shown a meaningful improvement in forced expiratory volume for one second, or FEV1, a key test for the health of cystic fibrosis patients.

Following this news, Arcturus's stock price fell over 50% on October 22, 2025. To obtain additional information, go to:

https://zlk.com/pslra-1/arcturus-therapeutics-holdings-inc-lawsuit-submission-form?prid=174169&wire=1&utm_campaign=54

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire